CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project develops a peptide-based drug to target and reduce tumor stroma in pancreatic cancer, enhancing chemotherapy effectiveness. The drug, AV3, shows promise in reducing fibrosis and achieving significant tumor regression in preclinical models.
Pancreatic cancer is a devastating disease with a median 5-year survival rate of 3-5%.
One explanation for the dismal prognosis is the failure of many chemotherapies.
Pancreatic tumor cells stimulate neighbouring non-tumor cells (stromal cells) to join and grow around them.
This stroma forms a fibrous matrix that promotes 1) aggressive tumor growth, 2) distant metastasis, and 3) form a barrier to chemotherapy and drug delivery.
There is a high need to enhance the success of pancreatic cancer tre…
SCARTEC THERAPEUTICS BV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
